420
Views
5
CrossRef citations to date
0
Altmetric
REVIEW

Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review

, ORCID Icon, ORCID Icon, , , ORCID Icon, & ORCID Icon show all
Pages 755-774 | Received 28 Mar 2023, Accepted 28 Jun 2023, Published online: 21 Jul 2023

References

  • Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49(5):1601526. doi:10.1183/13993003.01526-2016
  • Hallstrand TS, Leuppi JD, Joos G, et al. ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. Eur Respir J. 2018;52(5):1801033. doi:10.1183/13993003.01033-2018
  • Gauvreau GM, El-Gammal AI, O’Byrne PM. Allergen-induced airway responses. Eur Respir J. 2015;46(3):819–831. doi:10.1183/13993003.00536-2015
  • Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999;159(4):1043–1051. doi:10.1164/ajrccm.159.4.9806052
  • Lauzon AM, Martin JG. Airway hyperresponsiveness; smooth muscle as the principal actor. F1000Res. 2016;5:306. doi:10.12688/f1000research.7422.1
  • Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002;346(22):1699–1705. doi:10.1056/NEJMoa012705
  • Siddiqui S, Mistry V, Doe C, et al. Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol. 2008;122(2):335–341. doi:10.1016/j.jaci.2008.05.020
  • Corry DB, Folkesson HG, Warnock ML, et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med. 1996;183(1):109–117. doi:10.1084/jem.183.1.109
  • Wills-Karp M, Rani R, Dienger K, et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J Exp Med. 2012;209(3):607–622. doi:10.1084/jem.20110079
  • Yang G, Volk A, Petley T, et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine. 2004;28(6):224–232. doi:10.1016/j.cyto.2004.08.007
  • Altman MC, Lai Y, Nolin JD, et al. Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling. J Clin Invest. 2019;129(11):4979–4991. doi:10.1172/JCI126402
  • Lai Y, Altemeier WA, Vandree J, et al. Increased density of intraepithelial mast cells in patients with exercise-induced bronchoconstriction regulated through epithelially derived thymic stromal lymphopoietin and IL-33. J Allergy Clin Immunol. 2014;133(5):1448–1455. doi:10.1016/j.jaci.2013.08.052
  • Al-Shaikhly T, Murphy RC, Parker A, et al. Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma. Eur Respir J. 2022;60:2101865. doi:10.1183/13993003.01865-2021
  • Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777–792. doi:10.1080/14728222.2020.1783242
  • Calzetta L, Aiello M, Frizzelli A, et al. The impact of monoclonal antibodies on airway smooth muscle contractility in asthma: a systematic review. Biomedicines. 2021;9(9):1281. doi:10.3390/biomedicines9091281
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
  • Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
  • Boulet LP, Chapman KR, Côté J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997;155(6):1835–1840. doi:10.1164/ajrccm.155.6.9196083
  • Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155(6):1828–1834. doi:10.1164/ajrccm.155.6.9196082
  • Fahy JV, Cockcroft DW, Boulet LP, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med. 1999;160(3):1023–1027. doi:10.1164/ajrccm.160.3.9810012
  • Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol. 2003;131(1):46–52. doi:10.1159/000070434
  • Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–593. doi:10.1164/rccm.200312-1651OC
  • Prieto L, Gutiérrez V, Colás C, et al. Effect of omalizumab on adenosine 5’-monophosphate responsiveness in subjects with allergic asthma. Int Arch Allergy Immunol. 2006;139(2):122–131. doi:10.1159/000090387
  • Patel BM, Chiang DT, Clark JP, Romero FA, Casale TB. 1022 Effects of omalizumab (Xolair®) on airway hyperresponsiveness. J Allergy Clin Immunol. 2009;123(2):S263. doi:10.1016/j.jaci.2008.12.1020
  • van Rensen EL, Evertse CE, van Schadewijk WA, et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy. 2009;64(1):72–80. doi:10.1111/j.1398-9995.2008.01881.x
  • Zielen S, Lieb A, De La Motte S, et al. Omalizumab protects against allergen-induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma. Int Arch Allergy Immunol. 2013;160(1):102–110. doi:10.1159/000339243
  • Hendeles L, Khan YR, Shuster JJ, Chesrown SE, Abu-Hasan M. Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy. Ann Allergy Asthma Immunol. 2015;114(1):58–62. doi:10.1016/j.anai.2014.10.012
  • Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144–2148. doi:10.1016/S0140-6736(00)03496-6
  • Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199–204. doi:10.1164/rccm.200208-789OC
  • Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. doi:10.1056/NEJMoa0808991
  • Gauvreau GM, Sehmi R, FitzGerald J, et al. 500 The effect of benralizumab on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol. 2021;147(2):AB157. doi:10.1016/j.jaci.2020.12.563
  • Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–2110. doi:10.1056/NEJMoa1402895
  • Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299–1312. doi:10.1016/S2213-2600(21)00226-5
  • Sverrild A, Hansen S, Hvidtfeldt M, et al. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2022;59(1):2101296. doi:10.1183/13993003.01296-2021
  • Scheerens H, Arron JR, Zheng Y, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy. 2014;44(1):38–46. doi:10.1111/cea.12220
  • Russell RJ, Chachi L, FitzGerald JM, et al. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respir Med. 2018;6(7):499–510. doi:10.1016/S2213-2600(18)30201-7
  • Revez JA, Bain LM, Watson RM, et al. Effects of interleukin-6 receptor blockade on allergen-induced airway responses in mild asthmatics. Clin Transl Immunology. 2019;8(6):e1044. doi:10.1002/cti2.1044
  • Gauvreau GM, Becker AB, Boulet LP, et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol. 2003;112(2):331–338. doi:10.1067/mai.2003.1689
  • Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354(7):697–708. doi:10.1056/NEJMoa050580
  • Rouhani FN, Meitin CA, Kaler M, Miskinis-Hilligoss D, Stylianou M, Levine SJ. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med. 2005;99(9):1175–1182. doi:10.1016/j.rmed.2005.02.031
  • Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370(9596):1422–1431. doi:10.1016/S0140-6736(07)61600-6
  • Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011;183(8):1007–1014. doi:10.1164/rccm.201008-1210OC
  • Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effect of an anti-M1 prime monoclonal antibody, MEMP1972A, in a phase II proof-of-activity allergen challenge study in patients with mild asthma. Am J Respir Crit Care Med. 2012;185:A6793.
  • Gauvreau GM, Hohlfeld JM, Grant S, et al. Efficacy and safety of an inhaled anti-TSLP antibody fragment in adults with mild atopic asthma. Am J Respir Crit Care Med. 2020;201:A4207.
  • Henig NR, Aitken ML, Liu MC, Yu AS, Henderson WR Jr. Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am J Respir Crit Care Med. 2000;162(2 Pt 1):523–527. doi:10.1164/ajrccm.162.2.9911084
  • Bryan SA, O’Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2149–2153. doi:10.1016/S0140-6736(00)03497-8
  • Gauvreau GM, Boulet LP, Cockcroft DW, et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy. 2014;44(1):29–37. doi:10.1111/cea.12235
  • Tajiri T, Niimi A, Matsumoto H, et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol. 2014;113(4):470–475 e472. doi:10.1016/j.anai.2014.06.004
  • Chan R, RuiWen Kuo C, Jabbal S, Lipworth BJ. Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma. J Allergy Clin Immunol. 2023;151(3):700–705. doi:10.1016/j.jaci.2022.10.028
  • Cahill KN, Katz HR, Cui J, et al. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med. 2017;376(20):1911–1920. doi:10.1056/NEJMoa1613125
  • Murphy RC, Chow YH, Lai Y, et al. Identification of mast cell progenitor cells in the airways of individuals with allergic asthma. Allergy. 2022;78:547–549. doi:10.1111/all.15498
  • Nakae S, Ho LH, Yu M, et al. Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice. J Allergy Clin Immunol. 2007;120(1):48–55. doi:10.1016/j.jaci.2007.02.046
  • Reuter S, Heinz A, Sieren M, et al. Mast cell-derived tumour necrosis factor is essential for allergic airway disease. Eur Respir J. 2008;31(4):773–782. doi:10.1183/09031936.00058907
  • Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75(2):311–325. doi:10.1111/all.13985
  • Menzies-Gow A, Corren J, Bourdin A, et al. Efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study (Abstract L46). J Allergy Clin Immunol. 2021;147(2):AB249.
  • Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975
  • Panettieri RA Jr, Sjöbring U, Péterffy A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018;6(7):511–525. doi:10.1016/S2213-2600(18)30184-X
  • Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781–796. doi:10.1016/S2213-2600(16)30265-X
  • Boulet LP, Gauvreau G, Boulay ME, O’Byrne P, Cockcroft DW. Clinical Investigative Collaboration CNoCoEA. The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies. Allergy. 2007;62(10):1101–1110. doi:10.1111/j.1398-9995.2007.01499.x
  • Davis BE, Illamperuma C, Gauvreau GM, et al. Single-dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J. 2009;33(6):1302–1308. doi:10.1183/09031936.00169008
  • Gauvreau GM, Lee JM, Watson RM, Irani AM, Schwartz LB, O’Byrne PM. Increased numbers of both airway basophils and mast cells in sputum after allergen inhalation challenge of atopic asthmatics. Am J Respir Crit Care Med. 2000;161(5):1473–1478. doi:10.1164/ajrccm.161.5.9908090
  • Parameswaran K, Liang H, Fanat A, Watson R, Snider DP, O’Byrne PM. Role for cysteinyl leukotrienes in allergen-induced change in circulating dendritic cell number in asthma. J Allergy Clin Immunol. 2004;114(1):73–79. doi:10.1016/j.jaci.2004.03.054
  • Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009;64(12):1728–1736. doi:10.1111/j.1398-9995.2009.02201.x
  • Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157–171. doi:10.1056/NEJMra2032506
  • Agache I, Antolin-Amerigo D, de Blay F, et al. EAACI position paper on the clinical use of the bronchial allergen challenge: unmet needs and research priorities. Allergy. 2022;77(6):1667–1684. doi:10.1111/all.15203
  • Haahtela T, Järvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991;325(6):388–392. doi:10.1056/NEJM199108083250603
  • Szefler S, Weiss S, Tonascia J, et al. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343(15):1054–1063.